| A serological assay to detect SARS-CoV-2 seroconversion in humans F Amanat, D Stadlbauer, S Strohmeier, THO Nguyen, V Chromikova, ... Nature medicine 26 (7), 1033-1036, 2020 | 2038 | 2020 |
| Robust neutralizing antibodies to SARS-CoV-2 infection persist for months A Wajnberg, F Amanat, A Firpo, DR Altman, MJ Bailey, M Mansour, ... Science 370 (6521), 1227-1230, 2020 | 1233 | 2020 |
| Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine F Krammer, K Srivastava, H Alshammary, AA Amoako, MH Awawda, ... New England Journal of Medicine 384 (14), 1372-1374, 2021 | 812 | 2021 |
| SARS‐CoV‐2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup D Stadlbauer, F Amanat, V Chromikova, K Jiang, S Strohmeier, ... Current protocols in microbiology 57 (1), e100, 2020 | 756 | 2020 |
| Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study STH Liu, HM Lin, I Baine, A Wajnberg, JP Gumprecht, F Rahman, ... Nature medicine 26 (11), 1708-1713, 2020 | 533 | 2020 |
| SARS-CoV-2 spike E484K mutation reduces antibody neutralisation S Jangra, C Ye, R Rathnasinghe, D Stadlbauer, H Alshammary, ... The Lancet Microbe 2 (7), e283-e284, 2021 | 401 | 2021 |
| A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial R Nachbagauer, J Feser, A Naficy, DI Bernstein, J Guptill, EB Walter, ... Nature medicine 27 (1), 106-114, 2021 | 254 | 2021 |
| Broadly protective human antibodies that target the active site of influenza virus neuraminidase D Stadlbauer, X Zhu, M McMahon, JS Turner, TJ Wohlbold, AJ Schmitz, ... Science 366 (6464), 499-504, 2019 | 197 | 2019 |
| Immunological imprinting of the antibody response in COVID-19 patients T Aydillo, A Rombauts, D Stadlbauer, S Aslam, G Abelenda-Alonso, ... Nature communications 12 (1), 3781, 2021 | 190 | 2021 |
| SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study AG Letizia, Y Ge, S Vangeti, C Goforth, DL Weir, NA Kuzmina, ... The Lancet Respiratory Medicine 9 (7), 712-720, 2021 | 167 | 2021 |
| Novel correlates of protection against pandemic H1N1 influenza A virus infection S Ng, R Nachbagauer, A Balmaseda, D Stadlbauer, S Ojeda, M Patel, ... Nature medicine 25 (6), 962-967, 2019 | 156 | 2019 |
| Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City D Stadlbauer, J Tan, K Jiang, MM Hernandez, S Fabre, F Amanat, C Teo, ... Nature 590 (7844), 146-150, 2021 | 141 | 2021 |
| The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. S Jangra, C Ye, R Rathnasinghe, D Stadlbauer, F Krammer, V Simon, ... MedRxiv, 2021 | 137 | 2021 |
| SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months A Wajnberg, F Amanat, A Firpo, DR Altman, MJ Bailey, M Mansour, ... MedRxiv, 2020.07. 14.20151126, 2020 | 123 | 2020 |
| The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera R Rathnasinghe, S Jangra, A Cupic, C Martínez-Romero, LCF Mulder, ... MedRxiv, 2021 | 113 | 2021 |
| Surveillance of European domestic pig populations identifies an emerging reservoir of potentially zoonotic swine influenza A viruses D Henritzi, PP Petric, NS Lewis, A Graaf, A Pessia, E Starick, A Breithaupt, ... Cell Host & Microbe 28 (4), 614-627. e6, 2020 | 91 | 2020 |
| Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans AH Ellebedy, R Nachbagauer, KJL Jackson, YN Dai, J Han, WB Alsoussi, ... Proceedings of the National Academy of Sciences 117 (30), 17957-17964, 2020 | 64 | 2020 |
| Differential T-cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers R da Silva Antunes, S Pallikkuth, E Williams, E Dawen Yu, J Mateus, ... The Journal of infectious diseases 224 (1), 70-80, 2021 | 63 | 2021 |
| Pre-existing antineuraminidase antibodies are associated with shortened duration of influenza A (H1N1) pdm virus shedding and illness in naturally infected adults HE Maier, R Nachbagauer, G Kuan, S Ng, R Lopez, N Sanchez, ... Clinical Infectious Diseases 70 (11), 2290-2297, 2020 | 62 | 2020 |
| Sequential immunization with live-attenuated chimeric hemagglutinin-based vaccines confers heterosubtypic immunity against influenza A viruses in a preclinical ferret model WC Liu, R Nachbagauer, D Stadlbauer, A Solórzano, F Berlanda-Scorza, ... Frontiers in immunology 10, 450546, 2019 | 55 | 2019 |
